MK-8690 Clinical Trials (2026): 1 Studies for Colitis Ulcerative & Ulcerative Colitis
Hipa.ai Research · Source: ClinicalTrials.gov / AACT
Synced daily from ClinicalTrials.gov via AACT. Last sync: .
1 MK-8690 clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 1 indication (including Colitis Ulcerative & Ulcerative Colitis) and 100 total planned enrollment. 1 MK-8690 clinical trial is actively recruiting at 9 U.S. sites across 7 states. Most recent activity: NCT07463183 (Dec 2028).
Where to Participate: All MK-8690 Trial Sites in the U.S. (9 sites across 7 states)
Every actively recruiting MK-8690trial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.
| State | Facility | City | Trial | Map |
|---|---|---|---|---|
| CA | Clinnova Research ( Site 1042) | Anaheim92805 | NCT07463183 | Map |
| CO | Peak Gastroenterology Associates ( Site 1052) | Colorado Springs80907 | NCT07463183 | Map |
| CO | South Denver Gastroenterology, PC ( Site 1068) | Englewood80113 | NCT07463183 | Map |
| FL | Nature Coast Clinical Research ( Site 1045) | Inverness34452 | NCT07463183 | Map |
| FL | Research Associates of South Florida - Miami - Southwest 8th Street ( Site 1072) | Miami33134 | NCT07463183 | Map |
| GA | Gastroenterology Associates of Central Georgia ( Site 1060) | Macon31201 | NCT07463183 | Map |
| KS | University of Kansas Medical Center ( Site 1077) | Kansas City66160 | NCT07463183 | Map |
| LA | Tulane University School of Medicine ( Site 1073) | New Orleans70112 | NCT07463183 | Map |
| MO | BVL Research - Kansas ( Site 1054) | Liberty64068 | NCT07463183 | Map |
MK-8690 clinical trials at a glance: phase × recruitment status
| Phase | recruiting | Total |
|---|---|---|
| P2 | 1 | 1 |
Recruiting MK-8690 clinical trials (1)
Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).
| NCT ID | Title | Phase | Indication | Enrollment | Started |
|---|---|---|---|---|---|
| NCT07463183 | MK-8690-002A Study to Evaluate Efficacy and Safety of MK-8690 in Participants With Moderately to Severely Active Ulcerative Colitis (MK-8690-002) | P2 | Colitis Ulcerative | 100 | Mar 2026 |
MK-8690 pivotal trial highlights (Phase 2/3/4)
Phase-2/3/4 studies with named acronyms — the registration-grade trials most cited in label discussions and Wikipedia.
| Acronym | NCT | Phase | Status | Indication | Enrollment | PubMed |
|---|---|---|---|---|---|---|
| MK-8690-002 | NCT07463183 | P2 | recruiting | Colitis Ulcerative | 100 | — |
All MK-8690 trials (1)
Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.
| NCT ID | Acronym | Title | Phase | Status | Enrollment | Sponsor | Started |
|---|---|---|---|---|---|---|---|
| NCT07463183 | MK-8690-002 | A Study to Evaluate Efficacy and Safety of MK-8690 in Participants With Moderately to Severely Active Ulcerative Colitis (MK-8690-002) | P2 | recruiting | 100 | Merck Sharp & Dohme LLC | Mar 2026 |
MK-8690 clinical trials: frequently asked questions
- How many MK-8690 clinical trials are there?
- 1 MK-8690 clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 1 is actively recruiting participants.
- Are MK-8690 clinical trials recruiting in 2026?
- Yes — 1 MK-8690 trial is actively recruiting in 2026, with 9 U.S. sites across 7 states. See the recruiting trials and the per-state site list further down this page.
- What conditions is MK-8690 being studied for?
- MK-8690 is being studied for Colitis Ulcerative, Ulcerative Colitis. The trials are grouped by indication on this page.
- What phase is MK-8690 in?
- MK-8690 clinical trials span 1 Phase 2. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
- Who sponsors MK-8690 clinical trials?
- The lead sponsor across the most MK-8690 trials is Merck Sharp & Dohme LLC. Each trial row links to the full study detail page including sponsor information.
Sources and methodology
Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming MK-8690as an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.
Last refreshed .
Related pages on Hipa.ai: